Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bafilomycin refers to a family of toxic macrolide antibiotics produced by various Streptomyces species. The most widely studied member is bafilomycin A1. Bafilomycins are potent and specific inhibitors of vacuolar-type H+-ATPase (V-ATPase), an enzyme complex responsible for acidifying intracellular compartments such as lysosomes and endosomes. By inhibiting V-ATPase, bafilomycins prevent the acidification required for lysosomal proteases to function, thereby blocking autophagic flux at the stage of autophagosome-lysosome fusion and subsequent degradation. This mechanism makes them valuable research tools in studies of autophagy and endosomal trafficking. Bafilomycins also exhibit anti-tumor, anti-parasitic, immunosuppressant, antifungal activity and have been shown to impair mitochondrial function as potassium ionophores[1][2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bafilomycin.